

Smoking Addiction - Pipeline Review, H1 2017

<https://marketpublishers.com/r/S52563F8022EN.html>

Date: June 2017

Pages: 86

Price: US\$ 2,000.00 (Single User License)

ID: S52563F8022EN

Abstracts

Smoking Addiction - Pipeline Review, H1 2017

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Smoking Addiction - Pipeline Review, H1 2017, provides an overview of the Smoking Addiction (Central Nervous System) pipeline landscape.

In smoking addiction, people experience an uncontrollable dependence on cigarettes, which on stopping will cause severe mental, emotional or physical reactions. People addicted to smoking develop tolerance to nicotine. Nicotine acts on acetylcholine receptors causing the body to react to nicotine at these receptors in the same manner as it responds to acetylcholine. This leads to alterations in the activity and physiological functions of many brain systems. This causes structural and functional changes in the brains of smokers. Upon sudden nicotine withdrawal, the brain and other parts of the body get disturbed, leading to a condition called withdrawal syndrome. The body usually takes time to function in the absence of nicotine. The effects of smoking withdrawal stem from the lack of nicotine that can be overcome by nicotine replacement therapies such as the use of nicotine patch or nicotine chewing gum.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Smoking Addiction - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Smoking Addiction (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and

development history and latest news and press releases.

The Smoking Addiction (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Smoking Addiction and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 5, 8, 6, 3 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.

Smoking Addiction (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Smoking Addiction (Central Nervous System).

The pipeline guide reviews pipeline therapeutics for Smoking Addiction (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Smoking Addiction (Central Nervous System) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Smoking Addiction (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Smoking Addiction (Central Nervous System)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Smoking Addiction (Central Nervous System).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Smoking Addiction (Central Nervous System) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying

prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

| |
|--|
| Introduction |
| Global Markets Direct Report Coverage |
| Smoking Addiction - Overview |
| Smoking Addiction - Therapeutics Development |
| Pipeline Overview |
| Pipeline by Companies |
| Pipeline by Universities/Institutes |
| Products under Development by Companies |
| Products under Development by Universities/Institutes |
| Smoking Addiction - Therapeutics Assessment |
| Assessment by Target |
| Assessment by Mechanism of Action |
| Assessment by Route of Administration |
| Assessment by Molecule Type |
| Smoking Addiction - Companies Involved in Therapeutics Development |
| Aradigm Corp |
| Bionex Pharmaceuticals LLC |
| Bioprojet SCR |
| CoMentis Inc |
| Embera NeuroTherapeutics Inc |
| Invion Ltd |
| Jeil Pharmaceutical Co Ltd |
| Johnson & Johnson |
| Lotus Pharmaceutical Co Ltd |
| NAL Pharmaceuticals Ltd |
| Pfizer Inc |
| Rock Creek Pharmaceuticals, Inc. |
| Selecta Biosciences Inc |
| Sopharma AD |
| Zynerba Pharmaceuticals Inc |
| Smoking Addiction - Drug Profiles |
| (metyrapone + oxazepam) - Drug Profile |
| Product Description |
| Mechanism Of Action |
| R&D Progress |
| AKR-214 - Drug Profile |
| Product Description |

Mechanism Of Action

R&D Progress

amitifadine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Anatabine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AT-1001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BP-1.4979 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cytisine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GTS-21 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JLP-1603 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JNJ-39393406 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

nadolol - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NFL-101 - Drug Profile

Product Description
Mechanism Of Action
R&D Progress
NIC-7DT - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
nicotine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
nicotine bitartrate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
nicotine bitartrate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PF-06413367 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SEL-068 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SEL-070 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Agonize Alpha 4Beta 2 and Alpha 6Beta 2 Neuronal Nicotinic
Receptor for Smoking Cessation - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize Cannabinoid Receptor for Smoking Addiction - Drug
Profile
Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit Sodium Dependent Dopamine, Noradrenaline and Serotonin Transporters for Appetite Suppression and Smoking Cessation - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Agonize Neuronal Nicotinic Acetylcholine Receptor for Smoking Cessation - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize CHRNA3 and CHRNA4 for Smoking Cessation - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize CHRNA2 and CHRNA4 for Smoking Cessation - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

URB-694 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine for Smoking Addiction - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Smoking Addiction - Dormant Projects

Smoking Addiction - Discontinued Products

Smoking Addiction - Product Development Milestones

Featured News & Press Releases

May 11, 2017: Selecta Biosciences Commences Dosing in Phase 1 Clinical Trial of Nicotine Vaccine for Smoking Cessation and Relapse Prevention

Mar 08, 2017: Achieve Life Sciences and OncoGenex Pharmaceuticals Announce Cytisine Symposium at the Annual Society for Research in Nicotine and Tobacco Conference ("SRNT")

Oct 20, 2016: OWC Pharmaceutical Research Completes Development of Its Medical Cannabis Sublingual Tablet

Nov 17, 2015: Invion Phase 2 Smoking Cessation Data: Results of Ongoing Analysis

Oct 05, 2015: Invion Successfully Completes Phase 2 Study of INV102 to Aid Smoking Cessation

Jun 29, 2015: Invion completes dosing in key phase II clinical trial of oral INV102 in smoking cessation

Feb 02, 2015: Invion completes enrolment in its phase II trial of oral INV102 (nadolol) in smoking cessation

Jan 19, 2015: Invion Announces Positive Interim Data from Its Phase II Clinical Trial of Oral Inv102 (nadolol) in Smoking Cessation

Jul 01, 2014: Embera NeuroTherapeutics to Receive Grant for Clinical Trial Through New Crowd Funding Platform

Jan 29, 2014: FDA clears path for "Smoking Cessation" clinical trial of INV102 (nadolol)

Nov 11, 2013: Change to FDA reviewing division for smoking cessation clinical trial

Jul 22, 2013: INVION ANNOUNCES COMMENCEMENT OF PHASE II CHRONIC BRONCHITIS CLINICAL TRIAL

Dec 19, 2012: Invion Provides Update On INV102 Phase II Clinical Programs

Oct 17, 2012: Nabi Biopharma's Phase II Study Of NicVAX In Combination With Varenicline Does Not Meet Primary Endpoint

Mar 16, 2012: Embera And Collaborators Publish Paper In Psychopharmacology Supporting EMB-001 For Smoking Cessation

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Smoking Addiction, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd.1), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd.1), H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Smoking Addiction - Pipeline by Aradigm Corp, H1 2017

Smoking Addiction - Pipeline by Bionex Pharmaceuticals LLC, H1 2017

Smoking Addiction - Pipeline by Bioprojet SCR, H1 2017

Smoking Addiction - Pipeline by CoMentis Inc, H1 2017

Smoking Addiction - Pipeline by Embera NeuroTherapeutics Inc, H1 2017

Smoking Addiction - Pipeline by Invion Ltd, H1 2017

Smoking Addiction - Pipeline by Jeil Pharmaceutical Co Ltd, H1 2017

Smoking Addiction - Pipeline by Johnson & Johnson, H1 2017

Smoking Addiction - Pipeline by Lotus Pharmaceutical Co Ltd, H1 2017

Smoking Addiction - Pipeline by NAL Pharmaceuticals Ltd, H1 2017

Smoking Addiction - Pipeline by Pfizer Inc, H1 2017

Smoking Addiction - Pipeline by Rock Creek Pharmaceuticals, Inc., H1 2017

Smoking Addiction - Pipeline by Selecta Biosciences Inc, H1 2017

Smoking Addiction - Pipeline by Sopharma AD, H1 2017

Smoking Addiction - Pipeline by Zynerba Pharmaceuticals Inc, H1 2017

Smoking Addiction - Dormant Projects, H1 2017

Smoking Addiction - Discontinued Products, H1 2017

List Of Figures

LIST OF FIGURES

Number of Products under Development for Smoking Addiction, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Number of Products by Top 10 Targets, H1 2017
Number of Products by Stage and Top 10 Targets, H1 2017
Number of Products by Top 10 Mechanism of Actions, H1 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
Number of Products by Routes of Administration, H1 2017
Number of Products by Stage and Routes of Administration, H1 2017
Number of Products by Molecule Types, H1 2017
Number of Products by Stage and Molecule Types, H1 2017

COMPANIES MENTIONED

Aradigm Corp
Bionex Pharmaceuticals LLC
Bioprojet SCR
CoMentis Inc
Embera NeuroTherapeutics Inc
Invion Ltd
Jeil Pharmaceutical Co Ltd
Johnson & Johnson
Lotus Pharmaceutical Co Ltd
NAL Pharmaceuticals Ltd
Pfizer Inc
Rock Creek Pharmaceuticals, Inc.
Selecta Biosciences Inc
Sopharma AD
Zynerba Pharmaceuticals Inc

I would like to order

Product name: Smoking Addiction - Pipeline Review, H1 2017

Product link: <https://marketpublishers.com/r/S52563F8022EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/S52563F8022EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970